We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+2.37%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$11.5M
Cap. Flow
+$7.41M
Cap. Flow %
1.83%
Top 10 Hldgs %
76.7%
Holding
35
New
7
Increased
8
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$36.3M
2
LLY icon
Eli Lilly
LLY
+$33.9M
3
VTRS icon
Viatris
VTRS
+$26.5M
4
AERI
Aerie Pharmaceuticals
AERI
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$69.6M
2
BIVV
Bioverativ Inc. Common Stock
BIVV
+$18.7M
3
MDXG icon
MiMedx Group
MDXG
+$16.1M
4
GMED icon
Globus Medical
GMED
+$13.2M
5
MYGN icon
Myriad Genetics
MYGN
+$9.96M

Sector Composition

Rank Sector Weight
1 Healthcare 90.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYGN icon
26
Myriad Genetics
MYGN
$530M
– –
-518,800
Closed -$9.96M
OFIX icon
27
Orthofix Medical
OFIX
$455M
– –
-188,908
Closed -$7.21M
SEM
28
DELISTED
Select Medical
SEM
– –
-1,229,043
Closed -$8.84M
SNY icon
29
Sanofi
SNY
$104B
– –
-1,538,908
Closed -$69.6M
THC icon
30
Tenet Healthcare
THC
$20.1B
– –
-484,300
Closed -$8.58M
VXRT
31
DELISTED
Vaxart
VXRT
– –
-156,834
Closed -$1.13M
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-195,289
Closed -$2.85M
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-313,296
Closed -$4.18M
DPLO
34
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
– –
-445,200
Closed -$7.1M
BIVV
35
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-343,800
Closed -$18.7M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Senzar Asset Management held 35 positions worth $406M, up 2.9% from $395M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Senzar Asset Management's Q2 2017 filing shows 7 new, 8 increased, 8 reduced and 12 closed positions. Its largest new stake was Neurocrine Biosciences: 749,200 shares worth $34.5M. The largest sale was Sanofi, an estimated $69.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier.

  • Senzar Asset Management's largest Q2 2017 buy was Neurocrine Biosciences: 749,200 shares worth $34.5M.
  • Senzar Asset Management added most to Viatris in Q2 2017, an estimated $26.5M increase.
  • Senzar Asset Management's biggest Q2 2017 reduction was Elevance Health, cutting an estimated $4.69M.
  • Senzar Asset Management fully exited Sanofi in Q2 2017, selling an estimated $69.6M.
  • Senzar Asset Management's ten largest holdings make up 77% of its $406M portfolio in Q2 2017.
  • Senzar Asset Management opened 7 new positions and closed 12 in Q2 2017.
  • Senzar Asset Management's portfolio value rose 2.9% quarter-over-quarter to $406M.

Based on Senzar Asset Management's 13F filing for Q2 2017, filed 11 Aug 2017.